Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Pfizer (NYSE:PFE | PFE Price Prediction) paid shareholders $0.43 per share on September 1, 2026, the fourth consecutive quarter at that rate. The check itself is unremarkable. The yield attached to it stands out. Pfizer trades near $29.02, and the trailing annualized payout of $1.72 produces a headline yield around 6%. That yield exists because the stock has spent years going the wrong direction, while management has held capital returns flat.
Price Chart Explains the 6% Yield
Pfizer is up 24.38% over the past year and 22.62% year to date, but the five-year picture tells the real story: shares are down 19.19% since September 2021, when they traded at $35.92. Falling prices mechanically inflate yields. With the 10-year Treasury at 4.75%, Pfizer’s premium over the risk-free rate is real but hardly generous once you factor in equity risk.
Cash Coverage Runs Razor-Thin
Pfizer paid out $9.77 billion in dividends in 2025 against operating cash flow of $11.71 billion and capital expenditures of $2.63 billion. That leaves a razor-thin cushion. The second quarter of 2026 was worse: operating cash flow of $3.45 billion versus a dividend payout of $2.45 billion, further pressured by a $2.6 billion final TCJA repatriation tax payment.
Adjusted EPS came in at $0.77 for Q2 2026 and $0.75 for Q1, both beating estimates. Full-year 2026 guidance sits at $2.80 to $3.00 in adjusted EPS, which covers the $1.72 annual payout with room to spare. Notably, Pfizer has run no meaningful buyback in 2025 or 2026, meaning the dividend is doing all the shareholder-return work.
Management Draws a Line in the Sand
CEO Albert Bourla addressed the elephant on the August call directly: “We feel extremely confident that we will, even the most stretched scenarios that we are running, we will be able to maintain our dividend.” He added that growth resumes “after the LOE period.” Translation: the payout holds through the loss-of-exclusivity trough, but do not expect meaningful hikes until Pfizer clears the $1.5 billion 2026 LOE headwind.
Scorecard: B-Minus Dividend
Yield: attractive on paper, engineered by price weakness. Growth: penny bumps annually, from $0.42 to $0.43 in 2025. Coverage: acceptable on earnings, tight on cash. Balance sheet: leverage at 2.7 times. Grade: a B-minus dividend backed by a management team that has staked its credibility on not cutting it.
Contact [email protected] for any questions or corrections.
Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics. Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications. A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.
